GlassScriptPhysician profile
Venkat R Vavilala
NPI 1730186081
$8,077.67
in general payments reported to CMS, 2019-2025
42 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $433 · 2021: $760 · 2022: $1,523 · 2023: $1,147 · 2024: $1,626 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Education: $61.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.08 |
| Education | $61.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $813.07 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $764.94 | 2019-2024 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $691.96 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $628.30 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.64 | 2019-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $447.24 | 2022-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $379.64 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $329.06 | 2019-2025 | Ozempic |
| Travere Therapeutics, INC. | $323.64 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $314.45 | 2020-2024 | Terlivaz |
| Lilly USA, LLC | $301.21 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $287.93 | 2022-2024 | Watchman Flx |
| Ethicon INC. | $261.52 | 2023 | Monarch Platform |
| Opko Pharmaceuticals, LLC | $154.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $152.29 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkat Vavilala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.